Early Access — free while we kick the tires
EdgarHawk

DMAC DiaMedica Therapeutics Inc. Insider Trading

7 filings analyzed · Latest 2025-12-08
Insider buys
7
Insider sells
0
Unique insiders
3
Direction
Net buying

Historically, high-priority insider buys have outperformed the S&P 500 by a median ~2% over the 30 days after filing — the edge is concentrated in that first month (n ≈ 5,751, 2021-2026). Past results don't predict the future. How we measure this ↗

December 2025
2025-12-08
high
1,061,277 shares
$7,631,469
@ $7.19
Significance 8/10

10% owner Jan Stahlberg purchases 1,061,277 shares ($7.6M) across 7 days at blended $7.19; now holds 8,825,742 shares (+13.7%)

Jan Stahlberg, a 10% owner at DiaMedica Therapeutics, executed 7 separate purchases totaling 1,061,277 shares for $7,631,469.23 between November 17–25, 2025, at prices ranging from $6.52 to $8.57. This represents a 13.7% increase in his holdings and occurs within the context of a 30-day stock price appreciation of +48.0% and a 90-day rise of +21.5%, despite the company reporting negative fundamentals (net income of $-8,620,000.00 for the most recent fiscal year). His prior 5 purchases at this same ticker over August 2025 all posted positive 90-day returns, with a perfect timing pattern; however, this current multi-day accumulation introduces questions about valuation—the company is unprofitable with quarterly revenue of only $500,000.00 yet maintains a market cap of $456,198,365.64, and the current price of $8.76 sits near the 52-week high of $9.12. The series of purchases at steadily escalating prices (with a +21.5% gain over just 7 calendar days from first to last transaction) diverges from his August pattern and warrants examination of whether this reflects conviction in a turnaround or execution against prior commitment.

September 2025
2025-09-04
high
1,000,000 shares
$5,958,107
@ $5.96
Significance 7/10

10% Owner STAHLBERG JAN buys 1,000,000 shares ($5.96 blended avg) across 9 transactions; holdings rise to 7.76M shares (+14.8%)

STAHLBERG JAN, a 10% owner of DiaMedica Therapeutics, executed 9 separate open-market purchases totaling 1,000,000 shares for $5,958,106.80 between August 13–27, 2025, at a blended average price of $5.96. This represents a substantial 14.8% increase to his post-transaction holdings of 7.76M shares. The company remains unprofitable (net income of $-7.7M in its most recent full fiscal year) with minimal revenue ($500,000.00 in the latest quarter), yet the insider has demonstrated a consistent pattern of accumulation: his prior trade at this same ticker on 2025-07-23 achieved a 30-day return of +74.6%, and his 2024-06-28 purchase at DMAC yielded a 90-day return of +72.0%. Across his broader cross-ticker history, he has maintained a 100% win rate at the 90-day mark with an average return of +72.0%. The current price of $5.37 stands 19.2% below the 52-week high but 29.7% above the 90-day baseline, indicating recent upward momentum that followed his prior July transaction.

July 2025
2025-07-25
high
400,000 shares
$1,400,000
@ $3.50
Significance 7/10

10% Owner JACINTO RICHARD II buys 400,000 shares ($1.4M) at $3.50; cluster pattern with 2 other insiders in 14 days

JACINTO RICHARD II, a 10% owner, purchased 400,000 shares at $3.50, increasing his holdings to 4,958,823 shares (4.96M shares) and representing an 8.8% increase in his position. This transaction is part of a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days. The company is unprofitable with a net income of $-7,707,000.00 ($-7.7M) and minimal quarterly revenue of $500,000.00 ($500.0K), yet the stock has risen 27.8% over the past 30 days and 25.0% over 90 days. The purchase price of $3.50 is 30.7% below the current price of $5.05 and 47.2% below the 52-week high of $6.65, indicating the shares were acquired during a recent dip. The coordinated buying by multiple insiders during a loss-making period, combined with recent positive price momentum, merits close investor scrutiny of the company's operational trajectory and potential catalysts for the recent rally.

2025-07-25
high
2,857,142 shares
$9,999,997
@ $3.50
Significance 6/10

10% owner Von Koch Thomas purchased 2,857,142 shares of DMAC for $10.0M on 2025-07-23; cluster buy pattern with 2 other insiders.

Von Koch Thomas, a 10% owner, deployed $9,999,997.00 ($10.0M) to acquire 2,857,142 shares at $3.50, expanding holdings by 51.7% to 8,383,577 shares. This represents a significant capital commitment at a price 30.7% below the current market level of $5.05 and 47.2% below the 52-week high of $6.65. The timing context is mixed: his prior buy at DMAC on 2024-06-28 at this ticker delivered +45.6% in 30 days and +72.0% in 90 days, whereas his 2023-06-23 buy produced only +6.2% at 30 days and -11.8% at 90 days, reflecting inconsistent near-term outcomes on this security. The transaction also coincides with a cluster pattern—2 other insiders bought within the past 14 days—which may indicate coordinated or reactive signaling, though the company remains unprofitable with net income of $-7,707,000.00 on quarterly revenue of $500,000.00. Stock has risen 27.8% over 30 days and 25.0% over 90 days, suggesting momentum may predate or follow this filing's disclosure.

2025-07-25
high
1,542,857 shares
$5,400,000
@ $3.50
Significance 7/10

10% Owner Jan Stahlberg buys 1,542,857 shares of DMAC at $3.50 for $5.4M, increasing stake 29.5%; 2 other insiders bought within 14 days

Stahlberg, a 10% owner, purchased 1,542,857 shares at $3.50 on 2025-07-23, increasing his holdings from 5,221,608 to 6,764,465 shares. This follows his prior DMAC purchase on 2024-06-28, which posted 90-day gains of 72.0%. Current price of $5.05 is -24.1% from the 52-week high of $6.65 but reflects 30-day appreciation of 27.8%. The company is unprofitable with -$7.7M net income in its most recent fiscal year and only $500,000 in latest quarterly revenue. A cluster pattern exists: 2 other insiders also bought within the past 14 days, suggesting coordinated accumulation despite fundamentals showing significant losses.

July 2024
2024-07-01
high
1,200,000 shares
$3,000,000
@ $2.50
Significance 6/10

10% owner Stahlberg purchases 1,200,000 shares of DMAC at $2.50 for $3,000,000.00, expanding stake to 5,221,608 shares.

Stahlberg Jan, a 10% owner, acquired 1,200,000 shares (1.20M shares) at $2.50 on 2024-06-28 for a total of $3,000,000.00, increasing post-transaction holdings to 5,221,608 shares (5.22M shares) from 4,021,608 shares (4.02M shares), a net increase of +29.8% versus pre-transaction holdings. The transaction occurred when the stock was trading -33.0% from its 52-week high of $4.40, and the company continues to face fundamental challenges: latest quarterly revenue was $500,000.00 ($500.0K) while net income was negative at $-5,151,000.00 ($-5.2M), with the company unprofitable over its most recent full fiscal year. The size and timing of this substantial acquisition by an existing majority shareholder merit close examination of whether this reflects conviction in a recovery thesis or represents obligations tied to earlier commitments given the company's ongoing losses and compressed valuation relative to recent trading ranges.

2024-07-01
high
1,200,000 shares
$3,000,000
@ $2.50
Significance 6/10

10% owner Von Koch Thomas buys 1,200,000 shares of DMAC at $2.50 (June 28), increasing stake to 5,526,435 shares (+27.7%)

Von Koch Thomas, a 10% owner, deployed $3,000,000 to purchase 1,200,000 shares at $2.50 on 2024-06-28, expanding his holdings by 27.7% to 5,526,435 shares. The transaction occurs in a company with negative fundamentals—net income of $-5,151,000 and quarterly revenue of $500,000—that is unprofitable on a full-year basis, suggesting the purchase is not driven by strong operational momentum. At the current price of $2.95, the stock has recovered 1.7% over 30 days and 8.1% over 90 days, but remains 33.0% below its 52-week high of $4.40. Notably, his prior buy at this ticker on 2023-06-23 was poorly timed, showing a 90-day return of -11.8%, indicating a pattern of purchases that did not precede stock appreciation. This repeat accumulation at a depressed valuation deserves attention to understand whether the insider believes a turnaround is imminent or whether market conditions have shifted since the prior purchase.

More Chemicals and Allied Products companies

Get alerts for DMAC

Add DMAC to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access